Quick Summary
Integrix Health in Moorhead, MN provides root-cause functional medicine for POTS (Postural Orthostatic Tachycardia Syndrome) and dysautonomia, serving patients from Fargo ND, West Fargo ND, and across North Dakota and Minnesota. Dr. Paul M. Bekkum, DC, CCEP investigates the autonomic antibody burden, mast cell activation status, blood volume regulation, inflammatory drivers, and connective tissue factors that sustain autonomic nervous system dysfunction — then builds a targeted, sequenced intervention plan. Telehealth is available throughout ND and MN for patients whose orthostatic limitations make travel difficult. In-person at 22 6th Street North, Moorhead MN 56560.
Moorhead MN · Fargo ND · West Fargo ND
POTS & Dysautonomia Specialist Serving the Fargo-Moorhead Region
POTS patients in the Fargo-Moorhead area face a significant barrier: no local specialist who understands the full autonomic-immune-inflammatory picture. Cardiologists manage the tachycardia. Neurologists assess the autonomic function. Immunologists investigate the antibodies. No one investigates all three simultaneously — or looks at the mast cell, gut, or connective tissue drivers that are often upstream of all of them. As a POTS and dysautonomia specialist near Fargo ND, Dr. Paul M. Bekkum, DC, CCEP provides a systems-level functional medicine investigation designed to find what individual specialists miss.
POTS — Moorhead MN
In-person POTS and dysautonomia consultations at 22 6th Street North, Moorhead MN 56560. Initial visits include a full IFM Matrix assessment, autonomic history review, and functional lab panel design including autoimmune antibody and mast cell markers.
Dysautonomia — Fargo ND
Fargo-area POTS patients travel to Integrix Health for a comprehensive root-cause investigation that their local cardiologist or neurologist is not equipped to provide. POTS functional medicine near Fargo ND means investigating what triggered your autonomic dysfunction — not just managing its symptoms.
Telehealth — ND & MN
Many POTS patients cannot sustain prolonged upright travel during flares. Telehealth consultations and ongoing protocol management are available throughout North Dakota and Minnesota — making functional medicine accessible regardless of your orthostatic tolerance on any given day.
What Drives POTS
The Five Root Causes Functional Medicine Investigates in POTS
POTS is not a single disease — it is a clinical syndrome defined by dysautonomia (autonomic nervous system dysfunction) that can arise from several distinct biological mechanisms. Identifying which mechanism is primary in a given patient determines which intervention will be effective. The five most common functional medicine-identified POTS drivers are:
- Autoimmune Dysautonomia — autoantibodies against adrenergic (alpha-1, beta-1, beta-2) and muscarinic (M2, M3, M4) receptors impair autonomic signaling. These antibodies can be triggered by infection, including EBV and COVID-19. Measurable via specialized autonomic antibody panels.
- Mast Cell Activation Syndrome (MCAS) — mast cells release histamine, prostaglandins, and other vasoactive mediators that cause vascular instability, fluid shifts, and autonomic dysregulation. MCAS is found in a substantial percentage of POTS patients and often coexists with hEDS/HSD.
- Hypovolemia & Blood Volume Dysregulation — reduced plasma volume is documented in many POTS patients. Drivers include aldosterone deficiency, excessive sodium excretion, and inadequate fluid intake. Renin-aldosterone panel and 24-hour urine assessment identify this driver.
- Connective Tissue Hypermobility (hEDS/HSD) — hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders cause vascular laxity that allows excessive venous pooling in the lower extremities when upright, directly triggering the orthostatic tachycardia response.
- Post-Infectious Neurological Injury — viral illnesses including EBV, COVID-19, and enteroviruses can trigger autonomic neuropathy through direct nerve damage or via autoimmune antibody generation. Post-COVID POTS has been widely documented since 2020.
A 2021 study in Nature Cardiovascular Research found autoantibodies against adrenergic and muscarinic receptors in a significant proportion of POTS patients — providing a mechanistic explanation for autoimmune-mediated dysautonomia that functional medicine protocols can target through immune regulation strategies.
The Integrix POTS Protocol
The Overlap Picture
POTS, Hashimoto's, Fibromyalgia & ME/CFS — Why These Conditions Often Coexist
Many POTS patients are also diagnosed with Hashimoto's thyroiditis, fibromyalgia, ME/CFS, and mast cell activation syndrome. This is not coincidence — these conditions share overlapping biological mechanisms that functional medicine's systems-level approach is uniquely suited to address simultaneously.
Shared Immune Dysregulation
Autoimmune activity — whether directed at thyroid tissue (Hashimoto's), autonomic receptors (POTS), or driving systemic neuro-inflammation (fibromyalgia, ME/CFS) — reflects a common upstream failure of immune self-tolerance. Addressing gut permeability, molecular mimicry, and genomic immune variants benefits all of these conditions simultaneously.
Mast Cell as a Common Thread
Mast cell activation syndrome is found in elevated rates among patients with POTS, hEDS, ME/CFS, and fibromyalgia. Mast cell-derived histamine and prostaglandins drive vascular instability (POTS), pain amplification (fibromyalgia), fatigue (ME/CFS), and immune dysregulation — making MCAS investigation a priority in patients with overlapping presentations.
Autonomic Dysfunction Across Conditions
Small fiber neuropathy, reduced heart rate variability, and autonomic dysregulation are documented across fibromyalgia, ME/CFS, and POTS patient populations. The IFM Matrix approach maps the full autonomic and neurological burden — allowing a coordinated intervention that improves autonomic tone across all overlapping diagnoses rather than addressing each in isolation.
Clinical Evidence
What the Research Shows About POTS and Functional Medicine
The evidence base for a root-cause approach to POTS has expanded rapidly — particularly following the post-COVID POTS surge and growing documentation of autoimmune and mast cell mechanisms.
Autoimmune Antibodies Are Measurable in POTS
A 2021 study in Nature Cardiovascular Research identified autoantibodies against adrenergic (α1, β1, β2) and muscarinic (M2, M3, M4) receptors in a significant proportion of POTS patients — confirming an autoimmune mechanism in a substantial subset. These findings were replicated in post-COVID POTS populations, with 2022–2023 research consistently showing elevated autonomic receptor autoantibodies in long COVID patients with orthostatic symptoms. This mechanistic evidence supports targeted immune regulation strategies — not just beta-blockers — as the appropriate intervention when autoimmune POTS is confirmed.
MCAS Is Present in Up to 30–50% of POTS Patients
A 2019 study in the Journal of Allergy and Clinical Immunology found mast cell activation biomarkers in 17% of POTS patients at a tertiary dysautonomia center; broader clinical research and patient cohort data suggest 30–50% in hyperadrenergic POTS subsets. Mast cell-derived histamine directly impairs autonomic function by triggering sympathetic activation and vascular instability. When MCAS is identified, the treatment approach shifts entirely: low-histamine diet, DAO enzyme support, quercetin, and mast cell stabilizers become primary interventions — changing outcomes for patients who have not responded to standard POTS management.
HRV as a Biomarker of Autonomic Recovery
Heart rate variability (HRV) is an established biomarker of autonomic function and vagal tone. Multiple studies confirm significantly reduced HRV in POTS patients compared to healthy controls — reflecting parasympathetic deficiency and excessive sympathetic dominance. HRV-guided interventions including slow-breathing protocols, vagal tone stimulation techniques, omega-3 supplementation, magnesium, and polyphenol-rich dietary patterns have shown clinically meaningful HRV improvements in dysautonomia patients. Dr. Bekkum incorporates HRV assessment and parasympathetic support protocols across all POTS presentations at Integrix Health.
Post-COVID POTS: Documented Incidence and Mechanisms
A 2022 meta-analysis identified POTS incidence significantly elevated in COVID-19 survivors versus non-infected controls, with orthostatic symptoms persisting at 6-month follow-up in many patients. Three mechanisms are now supported by published evidence: (1) autoimmune autoantibody generation against autonomic receptors triggered by COVID-19 immune response, (2) direct small-fiber autonomic neuropathy from viral neurotropism, and (3) mast cell activation exacerbated by COVID-19 infection. Identifying which mechanism is dominant guides the intervention — viral antibody panels, autonomic receptor autoantibodies, and mast cell markers each inform a different therapeutic priority.
Treatment Comparison
Functional Medicine vs. Conventional POTS Treatments
Most POTS patients cycle through multiple specialists without anyone investigating the underlying mechanism. Here is how the approaches compare.
| Approach | Investigates Root Cause? | Tests Autoimmune/MCAS? | Typical Intervention | Long-Term Outlook |
|---|---|---|---|---|
| Functional Medicine (Integrix Health) | ✅ Autoimmune, MCAS, hypovolemia, connective tissue | ✅ Yes — full panels | Personalized to identified driver | ✅ Root-cause resolution possible |
| Cardiology | ❌ Manages tachycardia only | ❌ No | Beta-blockers, ivabradine | ⚠️ Symptom reduction only |
| Neurology / Autonomic Clinic | ⚠️ Tests autonomic function, not root cause | ⚠️ Sometimes | Tilt table test; fludrocortisone | ⚠️ Diagnosis + limited treatment |
| Primary Care | ❌ Generic advice | ❌ No | Salt loading, fluids, compression | ❌ Partial and temporary |
| Allergy / Immunology | ⚠️ MCAS only; not full picture | ⚠️ Partial | Antihistamines, cromolyn | ⚠️ Helps MCAS, not full POTS |
Know Before You Start
When Functional Medicine Is Right for POTS — and When to Seek Urgent Care First
POTS requires careful management, and some presentations need specialist evaluation before or alongside functional medicine investigation.
✅ Functional Medicine Is Appropriate When
- Confirmed POTS diagnosis (tilt table or active stand test)
- Orthostatic symptoms persisting despite salt, fluids, or beta-blockers
- Suspected MCAS overlap (flushing, histamine intolerance, allergic symptoms)
- Post-COVID or post-viral onset of autonomic symptoms
- Coexisting Hashimoto's, fibromyalgia, or ME/CFS
- Recurrent palpitations with no primary cardiac pathology found
- Fatigue and brain fog out of proportion to the tachycardia alone
🚨 Seek Urgent or Emergency Care If You Have
- Syncope with injury or loss of consciousness → ER evaluation
- Chest pain with tachycardia → rule out primary cardiac arrhythmia first
- Resting heart rate >150 without positional provocation → cardiology urgently
- Sudden severe headache or neurological changes → neurology emergency
- New orthostatic symptoms in pregnancy → OB or maternal-fetal medicine first
If you are unsure whether your presentation is appropriate for functional medicine, call us — Dr. Bekkum will advise on the right first step.
Common Questions
POTS & Dysautonomia — Frequently Asked Questions
What is POTS and how is it diagnosed?
POTS (Postural Orthostatic Tachycardia Syndrome) is an autonomic nervous system disorder defined by a heart rate increase of 30+ beats per minute within 10 minutes of standing, without a corresponding drop in blood pressure. It is typically confirmed with a tilt table test or active stand test. Symptoms include dizziness, lightheadedness, palpitations, fatigue, brain fog, nausea, and near-syncope when upright. Functional medicine's role is not to re-diagnose POTS but to investigate why — identifying the specific autoimmune, mast cell, hypovolemic, or connective tissue mechanism driving the autonomic dysfunction in each patient.
Can functional medicine help POTS?
Yes — and it is particularly valuable for POTS because conventional cardiology and neurology manage symptoms (beta-blockers, fludrocortisone, increased fluid and salt) without investigating root causes. Functional medicine investigates the autoimmune antibodies, mast cell activation, blood volume dysregulation, and inflammatory triggers that sustain autonomic dysfunction — allowing interventions that address the mechanism rather than only the downstream tachycardia. For autoimmune POTS, immune regulation strategies. For MCAS-driven POTS, low-histamine protocols. For hypovolemic POTS, mineralocorticoid and electrolyte optimization.
Is POTS connected to Hashimoto's or fibromyalgia?
Yes — substantial clinical overlap exists between POTS, Hashimoto's thyroiditis, fibromyalgia, ME/CFS, and mast cell activation syndrome. These conditions share underlying mechanisms: autoimmune dysregulation, autonomic nervous system sensitization, mast cell hyperreactivity, and connective tissue fragility. Many POTS patients carry two or more of these overlapping diagnoses. Integrix Health's IFM Matrix approach is specifically designed to address these overlapping presentations as a unified biological picture rather than treating each diagnosis in isolation.
What does POTS treatment look like at Integrix Health?
The initial POTS evaluation includes an IFM Matrix assessment, autonomic antibody panel, mast cell marker testing, renin-aldosterone panel, viral reactivation panel, inflammatory markers, thyroid full panel, and 3x4 Genetics SNP analysis. Based on findings, the intervention is tailored to the primary driver — immune regulation for autoimmune POTS, low-histamine dietary protocol and mast cell stabilizers for MCAS, electrolyte and aldosterone pathway support for hypovolemic POTS. Vagal tone support — including heart rate variability training and parasympathetic dietary protocols — is incorporated across all presentations.
Can I do POTS consultations via telehealth from Fargo, ND?
Yes. Telehealth consultations for POTS and dysautonomia are available throughout North Dakota and Minnesota. Given that POTS symptoms are often worsened by prolonged upright activity (including travel), telehealth is frequently the most appropriate format for initial evaluation and ongoing follow-up. Lab work can be ordered to local draw locations (LabCorp, Quest, or hospital outreach) without requiring travel to Moorhead.
Is POTS caused by COVID-19?
Post-COVID POTS is now one of the most well-documented forms of new-onset dysautonomia, with studies estimating 2–14% of long COVID patients developing orthostatic symptoms. The proposed mechanisms include: (1) autoimmune autoantibody generation against autonomic receptors triggered by the COVID-19 immune response, (2) direct autonomic nerve injury from viral neurotropism affecting small-fiber nerves, and (3) mast cell activation exacerbated by COVID-19 infection. At Integrix Health, post-COVID POTS evaluation includes viral antibody panels (COVID antibodies, EBV, HHV-6), autonomic receptor autoantibodies, and mast cell markers — identifying which mechanism is driving the autonomic dysfunction so the intervention targets the actual cause rather than managing only the tachycardia.
What is the difference between POTS and mast cell activation syndrome (MCAS)?
POTS and MCAS are distinct but frequently coexisting conditions. POTS is an autonomic nervous system disorder defined by orthostatic tachycardia. MCAS is an immune disorder in which mast cells release excessive mediators — histamine, prostaglandins, tryptase — in response to triggers, causing flushing, allergic reactions, digestive issues, and cardiovascular instability. The overlap occurs because mast cell-derived histamine directly impairs autonomic function, creating or worsening orthostatic tachycardia. Research suggests 30–50% of POTS patients have a significant MCAS component. Identifying MCAS requires specialized testing (serum tryptase, 24-hour urine histamine and prostaglandin D2) and fundamentally changes the treatment approach — adding low-histamine diet, DAO enzyme support, quercetin, and mast cell stabilizers as primary interventions alongside standard POTS management.
Can POTS get better, or is it a lifelong condition?
POTS outcomes vary significantly depending on the underlying driver and whether the root cause is identified and addressed. Adolescent POTS often improves substantially with time and targeted intervention. Autoimmune POTS can show meaningful improvement when immune dysregulation is addressed. MCAS-driven POTS typically improves significantly with low-histamine protocols and mast cell stabilization. Hypovolemic POTS often responds well to aldosterone pathway and electrolyte optimization. Post-COVID POTS has variable outcomes — some patients recover within 12 months while others have persistent symptoms requiring ongoing support. What drives treatment-resistant, persistent POTS is most commonly an unidentified root cause: an autoimmune driver that was never tested for, or an MCAS component that was never investigated. At Integrix Health, the goal is to identify that specific mechanism and build a targeted intervention — rather than indefinitely managing the downstream tachycardia.
Ready to Investigate Your Autonomic Dysfunction?
Find What's Actually Driving Your POTS
POTS patients deserve an investigation as complex as their condition. Functional medicine investigates the full autonomic-immune-inflammatory picture — not just the downstream tachycardia. Start with a free health assessment or book directly with Dr. Bekkum.